Biogen, Inc. (BIIB)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Biogen, Inc. (BIIB)
Company Performance

Current Price

as of Oct 11, 2024

$188.38

P/E Ratio

23.75

Market Cap

$27.47B

Description

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Metrics

Overview

  • HQCambridge, MA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerBIIB
  • Price$188.38-0.11%

Trading Information

  • Market Cap$27.47B
  • Float99.23%
  • Average Daily Volume (1m)1,344,892
  • Average Daily Volume (3m)1,096,596
  • EPS$7.97

Company

  • Revenue$9.29B
  • Rev Growth (1yr)0.09%
  • Net Income$583.60M
  • Gross Margin70.05%
  • EBITDA Margin34.48%
  • EBITDA$811.20M
  • EV$38.77B
  • EV/Revenue4.17
  • P/E23.75
  • P/S2.96
  • P/B1.73
Documents
SEC Filings
8-K (2024-09-12)
8-K (2024-08-14)
8-K (2024-08-01)
8-K (2024-06-25)
8-K (2024-04-24)
8-K (2024-02-13)
8-K (2023-12-12)
8-K (2023-11-08)
8-K (2023-09-26)
8-K (2023-09-01)
8-K (2023-07-31)
8-K (2023-07-28)
8-K (2023-07-25)
8-K (2023-06-29)
8-K (2023-05-03)
8-K (2023-04-25)
8-K (2023-04-18)
8-K (2023-03-09)
8-K (2023-02-15)
10-Q (2024-08-01)
10-Q (2024-04-24)
10-Q (2023-11-08)
10-Q (2023-07-25)
10-Q (2023-04-25)
10-K (2024-02-14)
10-K (2023-02-15)
Wikipedia
Biogen_Inc.
Factset Street Account
StreetAccount Metrics Recap - Biogen Q3 Earnings ($245.61, 0.00) (2023-11-08T12:09:22Z)
StreetAccount Earnings Call Q&A Summary: Biogen Q3 ($237.10, -8.51) (2023-11-08T14:48:29Z)
StreetAccount Consensus Metrics Preview - Biogen Q3 Earnings ($250.45, +0.95) (2023-11-06T16:51:17Z)
Street Takeaways - Biogen Q3 Earnings ($224.65, 0.00) (2023-11-10T13:45:27Z)
NICE recommends Roche's Columvi to treat relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (CHF 252.15, 0.00) (2023-10-17T02:33:39Z)
Biogen reports Q3 EPS $4.36 ex-items vs FactSet $3.97 [25 est, $3.11-4.50] - 8-K ($245.61, 0.00) (2023-11-08T12:08:44Z)
Biogen presents new data on BIIB090 in Early Alzheimer's Disease ($246.69, -5.42) (2023-10-25T14:58:24Z)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report (2023-11-08)
Earnings Report (2023-07-25)
Factset
Factset Business Description